Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the incorporation of a new wholly owned subsidiary under the name Lexaria Nutraceutical Corp. (“LEXX Nutra”). “LEXX Nutra will keep with Lexaria’s overall strategy of maximizing the company’s patented DehydraTECH(TM) technology in various markets. Lexaria has issued an exclusive, perpetual license to LEXX Nutra, allowing the use of DehydraTECH to create consumer packaged goods and/or intermediate ingredients composed of molecular compounds except those associated with nicotine or cannabis,” a recent article reads. “LEXX Nutra is also prohibited from using the licensing agreement for the manufacturing of any pharmaceutical product. Lexaria’s other wholly owned subsidiary, Lexaria Pharmaceutical Corp. (‘LEXX Pharma’), has had its licensing amended so that its sole focus is on manufacturing pharmaceutical products composed of any molecule except nicotine-associated molecules.”
To view the full article, visit https://ibn.fm/BEBCB
About Lexaria Bioscience Corp.
Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 35 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
For more information, please visit www.MissionIR.com
MissionIR is powered by IBN